Company news
Neuphoria Therapeutics Inc. news in 2024
Neuphoria Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
December 22, 2024
Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation
December 15, 2024
Results of Scheme Meeting
December 11, 2024
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
December 8, 2024
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
December 2, 2024
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
December 1, 2024
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
November 7, 2024
Bionomics to Present at the 2024 CNS Summit
November 6, 2024
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
November 3, 2024
Bionomics to Present at the ThinkEquity Conference
October 22, 2024
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
October 13, 2024
Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
October 6, 2024
Bionomics Limited announces intention to re-domicile to the United States
September 30, 2024
Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
July 30, 2024
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
July 28, 2024
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
July 17, 2024
Bionomics Limited Announces Private Placement of up to $70.0 Million
May 30, 2024
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 19, 2024
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
March 20, 2024
Bionomics to Present at the 2024 BIO CEO & Investor Conference
February 21, 2024
Bionomics Provides a Review of 2023 and of 2024 Plans
January 21, 2024
Bionomics to Present at Biotech Showcase™ 2024
January 4, 2024